Boston Scientific Corporation shares fell after its second-quarter results and CHAMPION-AF data release, according to TCW Concentrated Large Cap Growth Fund's Q2 2026 investor letter. The fund said results modestly beat expectations, but U.S. Electrophysiology and Watchman franchises missed consensus, and management lowered 2026 organic sales growth guidance to 10-11%. The CHAMPION-AF data released at the end of March hit all endpoints but failed to act as a positive catalyst for the stock. The fund believes current valuation may have overly discounted the company's long-term earnings growth profile, and shares remain under review. Boston Scientific closed at $51.42 per share on August 12, 2026, with a one-month return of 15.24% and a 52-week loss of 50.63%.
Boston Scientific CorpQ2 results missed consensus in key franchises and guidance cut for 2026 organic sales growth.
